Pancreatic ductal adenocarcinoma (PDAC) remains to be a therapeutic challenge as only 15%-20% of all patients present with resectable tumor stages by the time of diagnosis. In the remaining patients, either local tumor extension or systemic spread are obstacles for a surgical therapy as the only chance for long-term survival. With regard to local tumor extension, PDAC has been classified as resectable, borderline- ally not included in these definitions, but must be individually considered as a situation where conversion surgery-even with metastases resection-may be feasible in selected patients after neoadjuvant systemic treatment.
| BACKGROUND
Pancreatic cancer (PDAC) is one of the most aggressive solid tumor entities and the fourth leading cause for cancer-associated mortality in Western countries and shows an increasing incidence which will make it the second leading cause of cancer-associated deaths in 2030. 1, 2 Currently, only 15%-20% of all patients are candidates for upfront surgery at the time of diagnosis, which offers the chance of long-term survival, a proportion that has not significantly changed during the last two decades. 3 In the remaining 80%-85% of all patients, either a locally advanced or even metastatic stage of disease is found at the initial presentation. (NCCN). 6 Local resectability is generally defined as primary resectable PDAC, borderline resectable PDAC (BR-PDAC), or locally advanced PDAC (LA-PDAC). Metastatic PDAC (stage IV) is generally not included in these definitions, but must be individually considered as a situation where conversion surgery-even with metastases resection-may be feasible in selected patients after neoadjuvant systemic treatment. For the definition of local resectability and the decision for surgery, the extension of the tumor toward the vascular structures is of utmost importance. Since the 6th edition of the International Union against Cancer tumor staging system, venous infiltration and infiltration of adjacent organs represent a T3 stage, and only arterial involvement is regarded as T4 in PDAC. 9 Tumor extension should be evaluated by contrast-enhanced computed tomography (CE-CT) because this diagnostic modality achieves sensitivity and specificity rates of 63%-82% and 92%-100%, respectively, with regards to these issues. 10 In the case of contraindications for a CE-CT, MRI may be used instead of CE-CT; however, the accuracy of MRI is inferior to CE-CT regarding features of resectability in PDAC. 11 A prerequisite for the planning of a resection is the exclusion of distant metastases, which is done with regard to the liver by the abovementioned examinations. Furthermore, pulmonary spread should be excluded by conventional chest radiograph and thoracic CT scan in the case of any doubts.
Three recommendations are given by the above-mentioned consensus statements in the respective situations:
1. Patients with resectable PDAC should undergo surgical exploration and radical resection. 
| NEOADJUVANT THERAPY IN BORDERLINE RESECTABLE PANCREATIC CANCER
A large number of studies have investigated the effect of neoadjuvant treatment in BR-PDAC during the last decade. It needs to be emphasized that to date, all available data-except for one studyare retrieved from retrospective studies, and only one randomized controlled trial published in 2018 is available at the moment. The prior retrospective studies on BR-PDAC included between 13 and 203 patients. [14] [15] [16] [17] Mostly, chemoradiation was administered, including dosages between 30 and 60 Gy, and chemotherapy protocols with gemcitabine, 5-fluorouracil, or combinations with oxaliplatin and paclitaxel, respectively. These different clinical practice patterns reflect the wide variety of protocols and the lack of a standardized approach for neoadjuvant treatment in BR-PDAC. Clinically relevant toxicity in these publications depended on the chosen protocol and ranged between 9% and 58%. In a meta-analysis pooling these studies, most patients (46%) showed a stable disease stage, whereas a partial response was reported in 29%, and in 3% of the patients, a complete response was observed. 14 . 20 In this study, morbidity was 63% and in-hospital mortality 
| TH ERAPY OPTIONS IN LOCALLY ADVANCED PANCRE ATIC CANCER
In LA-PDAC, historically palliative treatment has been the standard of care in many institutions because the involvement of arterial structures has been regarded as a contraindication for surgery, and arterial resections in PDAC surgery have only been performed in a few patients in the past. 22, 23 The reasons for this include high morbidity when pancreatic surgery is combined with an arterial anastomosis, which ranges up to 100% in some publications, as well as a postoperative mortality of up to 46% in some series. 24 Besides these unacceptably high complication rates, oncologic outcomes after arterial resections during PDAC surgery have not been convincing, which was shown in a meta-analysis published in 2011. 24 Twelve studies reporting survival data on 170 patients showed that 1-and 3-year survival were clearly inferior to that of 1640 patients who underwent standard PDAC surgery. Regarding the specific topic of SMA involvement, a 2017 systematic review including 13 retrospective studies with 70 patients 25 has shown that resection and reconstruction of this vessel is on one hand associated with a high morbidity and a postoperative mortality of 20% and on the other hand results in a median survival of 11 months, which is not superior to a palliative treatment in the FOLFIRINOX era. 26 Consequently, upfront resection in LA-PDAC does in general not seem to be surgically feasible nor justified from an oncologic point of view, but is only accepted as an individual approach in highly selected patients today.
27-29
The Japanese Society of Hepato-Biliary-Pancreatic Surgery has published their experience with neoadjuvant therapy in initially unresectable PDAC in a 58-patient series in 2013 and has shown that an 8-month treatment before surgery is associated with a clearly superior outcome after an "adjuvant resection" than palliative treatment alone. resulting in a shift from the initial cT4 stage to lower stages and delineating tissue planes toward the arterial structures, allowing a standard resection afterward. 31, 32 In contrast to this clearly visible response in the case of downstaging, there is growing evidence that conventional imaging, that is, by standard CE-CT, fails to reflect the actual presence of viable tumor during restaging after completion of neoadjuvant treatment. 33, 34 This has been demonstrated in a 50-patient collective by Dholakia et al. 33 including both BR-PDAC and LA-PDAC, in which a resection rate of 58% was achieved, despite no significant changes in tumor volume or degree of vessel involvement in the two groups after completion of the neoadjuvant therapy.
The achievement of resection was impressively shown to be the decisive factor that determines survival in this study with a median survival of 23 months after resection, compared with 13.0 months, when resection could not be performed. Comparable results were described in 2015 by Ferrone and colleagues. 34 In this study, 40 patients were included: 26 of these patients were classified as LA-PDAC. The overall response rate was 90%, and the final R0 resection rate was 92%. Although a radiographic response was not seen is mandatory in many of these patients. The mentioned approach is comparable to the previously described radical "level 3" dissection in upfront PDAC surgery. 39 
| CURREN T PE RSPECTIVE
A major problem in the evaluation of neoadjuvant therapy in PDAC is the fact that the available evidence is mostly based on retrospective studies and that the applied treatment protocols differ to a great extent, that is, with regard to the use of radiation, the combination of different chemotherapy regimens, and the sequence as well as duration of treatment before surgery. Furthermore, in many studies, BR-PDAC and LA-PDAC are included, which makes comparisons difficult. Although in the last year several meta-analyses have been published, especially on the topic of Folfirinox in the neoadjuvant setting 14, [40] [41] [42] ; all of these fail to reach a high level of evidence due to the mentioned shortcomings. The reported resection rates after neoadjuvant therapy in these meta-analyses show a large heterogeneity, ranging between 0% and 43%, respectively. R0 resection rates vary between 55% and 100%, and median survival times between 9 and 43 months are reported. Despite these differing observations, all publications show that the achievement of resectability is the decisive factor to improve survival and that surgical resection after neoadjuvant treatment is not associated with higher rates of surgical morbidity or mortality compared with upfront resections. Although from these publications no valid conclusions can be drawn to define the most effective treatment regimens, which eventually lead to an increased rate of resectability for LA-PDAC, they show that the pool of patients who are candidates for surgery can be substantially extended when a neoadjuvant therapy is completed. A considerable number of trials are currently being conducted on national and international levels to investigate neoadjuvant therapy in BR-PDAC and LA-PDAC in a prospective setting.
Among them, gemcitabine is a standard drug in many protocols, combined with radiation, oxaliplatin, or capecitabine. Furthermore, combinations with nab-paclitaxel and radiation are under investigation for LA-PDAC, as well as Folfirinox in comparison to nab-paclitaxel and gemcitabine.
In summary, the various approaches to neoadjuvant PDAC therapy underline the importance of a multimodal strategy to improve outcomes in this fatal disease. There are encouraging results that effective chemotherapy protocols combined with or without radiation enhance the number of patients who can undergo surgical resection as the key to long-term survival despite an initially unresectable disease stage. Standardization of these protocols, however, remains poor to date. Presently recruiting and planned studies will increase evidence, and a change in clinical treatment pathways and guidelines can be expected in the near future, especially with regard to recommendations on BR-PDAC and LA-PDAC.
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